Condition: Plaque Psoriasis · Sponsor: Chipscreen Biosciences, Ltd.
" This study consists of two parts: Part 1 (Dose Escalation): A randomized, double-blind, placebo-controlled phase in which approximately 20 to 30 adult patients with plaque psoriasis will receive the investigational treatment for 4 weeks. Part 2 (Efficacy and Safety Assessment): A randomized, double-blind, placebo-controlled evaluation where approximately 200 adult patients with plaque psoriasis will undergo 12 weeks of treatment. The resulting data will provide preliminary evidence on the safety and efficacy profile of CS32582, informing its subsequent development strategy.
This description comes directly from the study's public registry record.
Jianzhong Zhang · 18001315877 · rmzjz@126.com
Always discuss trial participation with your own doctor first.
| Beijing Friendship Hospital, Capital Medical University | Beijing, Beijing Municipality, China | Not Yet Recruiting |
| Peking University People's Hospital | Beijing, Beijing Municipality, China | Not Yet Recruiting |
| Affiliated Hospital of Chengde Medical University | Chengde, Hebei, China | Not Yet Recruiting |
| The First Hospital of Hebei Medical University | Shijiazhuang, Hebei, China | Recruiting |
| Shiyan People's Hospital | Shiyan, Hubei, China | Not Yet Recruiting |
| Shandong Provincial Hospital for Skin Diseases | Jinan, Shandong, China | Not Yet Recruiting |
| First Hospital of Shanxi Medical University | Taiyuan, Shanxi, China | Not Yet Recruiting |
| The Second Affiliated Hospital of Xi'an Jiaotong University(Xibei Hospital ) | Xi’an, Shanxi, China | Not Yet Recruiting |
| Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University | Hangzhou, Zhejiang, China | Not Yet Recruiting |
| The Fourth Affiliated Hospital of Zhejiang University School of Medicine | Yiwu, Zhejiang, China | Not Yet Recruiting |
| The First Affliated Hospital of Wenzhou Medical University | Wenzhou, Zhengjiang, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07129382